Photodynamic effects of toluidine blue on human oral keratinocytes and fibroblasts and Streptococcus sanguis evaluated in vitro
Background and Objective Some oral bacteria are susceptible to killing by red light after their sensitization with toluidine blue O (TBO). The photochemotherapy of periodontal disease in vivo would require a therapeutic window where bacteria could be killed without adjacent normal tissue damage. Stu...
Saved in:
Published in: | Lasers in surgery and medicine Vol. 18; no. 3; pp. 253 - 259 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
New York
John Wiley & Sons, Inc
1996
Wiley-Liss |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background and Objective
Some oral bacteria are susceptible to killing by red light after their sensitization with toluidine blue O (TBO). The photochemotherapy of periodontal disease in vivo would require a therapeutic window where bacteria could be killed without adjacent normal tissue damage.
Study Design/Materials and Methods
The laser‐induced effects of TBO on normal human gingival keratinocytes and fibroblasts have been studied in vitro. For the assessment of viability, the CellTiter 96™ AQueous Non‐Radioactive Cell Proliferation Assay was used.
Results
TBO was cytotoxic at low concentrations (5.0 μg/ml). Sensitization of keratinocytes and fibroblasts with 2 and 5.0 μg/ml TBO, respectively, for 5 min and exposure to light from a 7.3 mW Helium/Neon (HeNe) laser for up to 2 min (0.876J) did not reduce cell viability. However, killing of Streptococcus sanguis was achieved following exposure to HeNe light for 75 sec (0.547J) in the presence of TBO at a concentration of 2.5 μg/ml.
Conclusion
The development of a system for the lethal photosensitization of bacteria responsible for periodontal disease may be possible. © 1996 Wiley‐Liss, Inc. |
---|---|
Bibliography: | istex:A54F8ED1BFAAAB841175740FC8A3648085AFD63D ark:/67375/WNG-TKMMGXVH-D ArticleID:LSM6 Zila Pharmaceutical ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0196-8092 1096-9101 |
DOI: | 10.1002/(SICI)1096-9101(1996)18:3<253::AID-LSM6>3.0.CO;2-R |